18-Gy craniospinal irradiation remains unsupported for unselected standard-risk medulloblastoma
Pooled five-year disease-control survival was 81.0% after 23.4-Gy CSI versus 71.3% after 18 Gy, supporting caution with further dose reduction.
Pooled five-year disease-control survival was 81.0% after 23.4-Gy CSI versus 71.3% after 18 Gy, supporting caution with further dose reduction.
In a 102-patient randomized trial, megestrol improved post-RT weight change by 3.81 kg versus standard care, predominantly through increased fat mass.
Among 89 breast cancer patients with at least three positive sentinel nodes, lymphedema was 3.1% with nodal irradiation versus 21.1% after axillary dissection.
In 378 prostate cancer patients, ten-year biochemical control was 79.6% with one HDR boost fraction versus 82.6% with two, while severe urinary toxicity differed.
After five years, biochemical control was 80.5% with single-fraction 24 Gy versus 85.1% with five-fraction 45 Gy, without proven equivalence.
In 271 recurrent glioblastoma patients, SRS doses above 19 Gy were associated with longer post-recurrence survival, without a demonstrated progression-free survival benefit.
The Hong Kong SBRT Study Group recommends risk-adapted local therapy for selected oncogene-driven NSCLC, including oligoresidual, oligoprogressive, and intracranial disease.
Across 88 cervical osteoradionecrosis cases, median onset was five years after RT; 41% developed epidural abscess and only 39% recovered fully.
ReCOG presents six clinical scenarios emphasizing individualized cumulative dose assessment, organ function, and situations where abdominal reirradiation should be withheld.
Among 52 HPV-positive oropharyngeal cancer patients, SAVER observed no contralateral nodal failures at median 31 months while reducing parotid dose.
Among 1,251 patients, 67% receiving curative and 80% receiving palliative radiotherapy reported at least one high-burden concern.
In two NSCLC cohorts, severe lymphopenia predicted worse survival before matching, but the association was no longer significant after accounting for disease burden.
In previously unirradiated cutaneous B-cell lymphoma lesions, one-year freedom from retreatment was 75% after 4 Gy versus 100% after 8–12 Gy.
Across 32 experts, agreement fell to Dice 0.45 for elective nasopharyngeal targets despite identical starting GTV and OAR contours.
One-year local control was 96.1% with single-fraction SRS and 96.6% with fractionated SRS across 2,460 small brain metastases.